India's New Drug Policy "Imminent"

24 July 1994

India's Chemicals and Fertilizers Minister, Ram lakham Singh Yadav, says the long-awaited new drug policy will be announced before August 15, ending two years of uncertainty and indecision. While foreign investors are awaiting the announcement they are not the sole targets of the new policy, he said; its delicensing features will be equally geared to encouraging the Indian sector to invest. India's last drug policy was announced in 1986.

The new policy is not expected to cover controlled drugs and their prices. There has been no consensus on the size of the basket of price-controlled drugs among government oficials, so it has reportedly been decided to defer this part of the policy document.

Rather, the two main planks of the policy are expected to be industry delicensing and incentives for basic research. Delicensing has been under consideration in the context of the industry policy of 1991, which placed the entire drug sector under compulsory licensing. Another major change is expected to be a cut in the number of drugs reserved for public-sector production. 15 products are currently reserved, under the 1986 policy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight